Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study

Bruce A. Hug,Christopher J. Matheny,Olivia Burns,Herbert Struemper, Xiaowei Wang,Michael L. Washburn

Clinical Therapeutics（2020）

引用 12|浏览2

暂无评分

摘要

•TLR4 agonist GSK1795091 has an acceptable safety profile in healthy participants•GSK1795091 was characterized by dose proportional increase in exposure•GSK1795091 stimulated transient and dose-dependent cytokine and immune cell changes

查看译文

关键词

cytokine,dose-escalation,GSK1795091,immunotherapy,pharmacokinetics,Toll-like receptor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要